Senesco preclinical data

In a mouse xenograft model of MM, twice-weekly 0.375 mg/kg IV SNS01-T plus 0.5 mg/kg bortezomib (89%, p=0.000003) or 0.2 mg/kg bortezomib (58.9%, p=0.0001) each significantly reduced tumor volume from baseline to 6 weeks vs. vehicle-treated controls. SNS01-T monotherapy reduced tumor volume at week 6 by 58.6% and high-dose bortezomib monotherapy reduced tumor growth by 38.6% vs. vehicle-treated controls (p=0.0021 and p=0.0035, respectively). Low-dose bortezomib non-significantly reduced tumor volume by 22.4% (p=0.1371). SNS01-T is a modified formulation of SNS01, a compound composed of a short interfering RNA (siRNA) against eukaryotic translation initiation factor 5A1(eIF5A), an eIF5A plasmid and polyethyleneiminie (PEI) ...